All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

imlunestrant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
estrogen antagonists, including estrogen receptor down-regulators	5783	2408840-26-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: imlunestrant imlunestrant tosilate LY3484356 LY-3484356 inluriyo	Imlunestrant is an estrogen receptor (ER) antagonist and selective estrogen receptor degrader (SERD). Imlunestrant binds to ER, blocks estrogen-mediated signaling, and induces ER degradation. Molecular weight: 524.52 Formula: C29H24F4N2O3 CLOGP: 6.39 LIPINSKI: 2 HAC: 5 HDO: 1 TPSA: 54.82 ALOGS: ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Sept. 25, 2025	FDA	ELI LILLY AND CO
Jan. 9, 2026	EMA	Eli Lilly Nederland B.V.
Dec. 22, 2026	PMDA	Eli Lilly Japan K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000000145	Estrogen Receptor Antagonists
FDA EPC	N0000175582	Estrogen Receptor Antagonist
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D065171	Estrogen Receptor Antagonists
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190113	Breast Cancer Resistance Protein Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Malignant neoplasm of breast	indication	254837009	DOID:1612

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 200MG BASE	INLURIYO	ELI LILLY AND CO	N218881	Sept. 25, 2025	RX	TABLET	ORAL	10654866	July 11, 2039	TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
EQ 200MG BASE	INLURIYO	ELI LILLY AND CO	N218881	Sept. 25, 2025	RX	TABLET	ORAL	11117902	July 11, 2039	TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 200MG BASE	INLURIYO	ELI LILLY AND CO	N218881	Sept. 25, 2025	RX	TABLET	ORAL	Sept. 25, 2030	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	ANTAGONIST	Ki	9.19		DRUG LABEL	DRUG LABEL
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN	ANTAGONIST	Ki	9.96		DRUG LABEL

External reference:

ID	Source
CHEMBL5095183	ChEMBL_ID
C000719756	MESH_SUPPLEMENTAL_RECORD_UI
4044290	VANDF
C5565130	UMLSCUI
CHEBI:747442	CHEBI
CHEMBL5095397	ChEMBL_ID
12039	INN_ID
D12216	KEGG_DRUG
146603228	PUBCHEM_CID
398152	MMSL
d10325	MMSL
020257	NDDF
12896	IUPHAR_LIGAND_ID
9CXQ3PF69U	UNII
2725912	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Inluriyo	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1717	TABLET, FILM COATED	200 mg	ORAL	NDA	30 sections